A case of percutaneous intracavitary amphotericin B instillation for the treatment of hemoptysis due to pulmonary aspergilloma.

Lee, Hong Lyeol; Cho, Hong Keun; Kim, Se Kyu; Chang, Joon; Kim, Sung Kyu; Lee, Won Young; Choe, Kyu Ok

doi:1992.39.2.180

Tuberc Respir Dis > Volume 39(2); 1992 > Article

Original Article

Tuberculosis and Respiratory Diseases 1992;39(2):180-185.
DOI: https://doi.org/10.4046/trd.1992.39.2.180 Published online April 1, 1992.

A case of percutaneous intracavitary amphotericin B instillation for the treatment of hemoptysis due to pulmonary aspergilloma.

Hong Lyeol Lee¹, Hong Keun Cho¹, Se Kyu Kim¹, Joon Chang¹, Sung Kyu Kim¹, Won Young Lee¹, Kyu Ok Choe²

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
²Department of Radiology, Yonsei University College of Medicine, Seoul, Korea

Abstract

The most common symptom associated with an pulmonary aspergilloma is hemoptysis, with estimates of frequency ranging from 50 to 85 percent of patients. Hemoptysis may be infrequent and minimal in amount or it may be severe with a fatal outcome. The major options available for the treatment of pulmonary aspergilloma include sugical resection of the lesion, a number of medical therapies, or simple observation of the patient for a time. Surgery is the treatment of choice but it is not feasible in some patients who have diffuse or advanced pulmonary disease that makes them poor candidates for thoracotomy. As an alternative to it, some categories of therapy including bronchial artery embolization and parenteral or endobronchial administration of antifungal drugs were tried without remarkable success. But percutaneous instillation of intracavitary amphotericin B for symptomatic aspergilloma has been reported with better results. The authors present a case of percutaneous intracavitary instillation of amphotericin B for the treatment of pulmonary aspergilloma and its successful result for the repetitive hemoptysis.